PubMed Health⌕ Search

Biomedical subjects

V Scudla

Publications and source records attributed to V Scudla.

At least 55 records · Page 3Linked to original sources
PubMed1994

[Clinical importance of the paraprotein index in multiple myeloma].

In a group of 54 patients with multiple myeloma, hitherto not treated by chemotherapy, the paraprotein index was assessed. It was revealed that this simple and readily available indicator is related to the degree of anaemia, the serum beta-2-microglobulin value, the degree of bone marrow infiltration by myeloma plasmocytes and the survival period. The authors found no relation to age, albumin, urea, creatinine, serum calcium values and degree of skeletal affection. It was revealed that values of the paraprotein index declined with the advancing disease evaluated according to Durie-Salmon's system. It may be said that the paraprotein index can be considered in patients with multiple myeloma an indicator which contributes to more profound knowledge of individual biological characteristics of the myeloma population and the prognosis of the disease.

Female↗
PubMed1994

[The cytokine network in multiple myeloma].

The authors review contemporary findings on the role of different components of the cytokine network from the aspect of development, prognosis and treatment of multiple myeloma. Greatest attention was devoted to the main growth factor of myeloma elements IL-6, but also to the real or so far sparsely elucidated role of other cytokines (IL-1, IL-2, GM-CSF, G-CSF, IL-3, IL-4, IL-5, IL-10, TNF, interferon alpha and gamma) under conditions in vitro and in vivo. For completeness sake the authors did not omit the problem of the soluble receptor of IL-2 and the role of TNF, TNF beta and in particular IL-1 beta in the pathogenesis of osteolytic lesions and the potential therapeutic role of antibodies against IL-6 (anti IL-6 mab) and interferon alpha and gamma.

Cytokines↗
PubMed1994

[Cytogenetic findings in patients with primary myelodysplastic syndrome and their prognostic significance. (Analysis of results in 65 patients)].

Cytogenetic examination of 65 patients with primary MDS revealed cytogenetic changes in 39 (60%) of the patients. The most frequently affected chromosomes were chromosomes 5, 7, 11, 17 and 20. Deletion of 5q only found in 9 (23%) of the patients with chromosomal changes occurred similarly as simple chromosomal changes most frequently in the prognostically more favourable group MDS-RA. Prognostically adverse monosomy of chromosome 7 was found in 3 patients in group RAEB and RAEB-t but only as part of complex chromosomal changes. The latter were encountered most frequently in patients of groups RAEB and RAEB-t, similarly as trisomy of chromosome 8. Patients in these groups had also a significantly shorter survival time (RAEB 17.7 and RAEB-t 14.2 months) than patients in group MDS-RA (31.5 months). Evaluation of survival according to Kaplan-Meyer's curve revealed significantly longer survival of patients without cytogenetic changes. Laboratory, cytogenetic and clinical findings in four patients with CMML differed from findings of the remaining patients with MDS. This supports the view that this sub-group is rather a myoproliferative conditions than MDS. Transformation to AL was proved in 19 patients. 14 of them (74%) had a chromosomal change at the time of diagnosis.

Adolescent↗
PubMed1994

[The role of iron deficiency on the development of anemia in patients on regular dialysis therapy].

In the course of regular dialyzation treatment very frequently iron deficiency develops. The objective of the work was to evaluate the participation of sideropenia in the development of the hypoproliferative component of anaemia and to evaluate the effectiveness of oral iron administration in a group of 24 dialyzed patients whose serum ferritin concentration was lower than 100 micrograms/l. Administration of 105 mg elemental iron per day (1 tablet of Ferronat retard, Spofa) for a period of 6 months led in 17 patients (71%) to a statistically significant increase of erythrocytes, serum ferritin, the iron plasma level and transferrin saturation. In these patients the mean haemoglobin value increased from 65 +/- 6 milligrams to 105 +/- 17 milligrams (increase by 40 milligrams), the mean number of red cells increased from 2.6 +/- 0.4 x 10(12)/l to 3.5 +/- 0.7 x 10(12)/l (increase by 0.9 x 10(12)/l) and the mean haematocrit increased from the initial value of 0.21 +/- 0.02 to 0.31 +/- 0.05 (increase by 0.10). In seven patients (29%) after oral substitution of iron deficiency no significant rise of any of the investigated indicators was observed. Four subjects of this group responded by a rise of red blood cells to intravenous iron administration and in the remaining three patients anaemia was favourably influenced by administration of recombinant erythropoietin (Eprex, Cilag). The results of the investigation provide conclusive evidence that iron deficiency plays a very important part in the development of anaemia in hemodialyzed patients. Substitution treatment with iron preparations extends the opportunities to treat anaemia during regular dialyzation treatment and is at the same time also very important from the economical aspect as it makes more expedient selection of patients suited for recombinant erythropoietin treatment possible.

Adult↗
PubMed1994

[Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].

In a group of 74 patients with multiple myeloma the authors revealed elevated values of serum thymidine kinase (REA kit ADICO Praha, range of normal values 0-5 U/l) in 40% of the patients-incl. a group of 22 subjects examined at the time of diagnosis of the disease in 50%, and a group of 52 subjects examined in different stages of the disease in 36% of the patients. If the upper range of S-TK 10 U/l was used, the ratio of patients with a raised value declined to 15%, in selected groups to 18 and 14% resp. The authors found a satisfactory correlation of serum thymidine values and values of S-beta-microglobulin, S-albumin, with the percentage ratio of plasmocytes in bone marrow and a less significant correlation was found with the red cell sedimentation rate (in IgG and IgA type) to the index of paraprotein and the serum interleukin-6 level. The authors did not reveal significant differences of serum thymidine kinase levels with regard to age, sex and immunochemical type of M-protein and type of light chains. The authors did not reveal any correlation of thymidine kinase serum levels and haemoglobin values, S-ferritin levels, the beta 2-microglobulin index and the synthetic score of plasma cells. It was found that examination of S-thymidine kinase extends in a useful way the existing spectrum of laboratory tests which help to elucidate the individual character of multiple myeloma.

Adult↗
PubMed1994

[Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].

In a group of 74 patients with multiple myeloma examined in different developmental stages of the disease the authors evaluated the clinical impact of assessment of the serum thymidine kinase (S-TK) activity. They recorded a significant relationship of S-TK values and the clinical activity of the disease (increase in 75% of the patients with the clinically active form of myeloma) and the general clinical condition ("performance status") evaluated by means of a five-grade scale. The authors tested the relationship of S-TK values and the degree of multiple myeloma, i.e. the clinical stage of the disease tested according to Durie-Salmon's classification (British Medical Research Council) and the authors' system modified according to Bataille. Individual stages of the disease (stage 1-3) differed as to the mean S-TK value and the median value and also as to the ratio of subjects with elevated values of this biochemical indicator. It was revealed that the cause of the relationship between S-TK and the stage of the disease is the increasing ratio of patients with the clinically active form of the disease in more advanced stages of myeloma. The S-TK activity in patients in the stable stage of the disease did not differ significantly in different stages (stage 1-3). From the practical aspect it is, however, an adverse finding that there is significant overlapping of S-Tk values in all mutually compared groups. According to preliminary experience S-TK is a simple readily accessible indicator related to proliferative characteristics of tumourous tissue which extends the hitherto available spectrum of evaluation criteria in multiple myeloma.

Adult↗
PubMed1993

[Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)].

In the submitted study the authors summarize experience with the treatment of resistant forms of multiple myeloma by a combination of Mitoxantrone, Vincristine and Prednisone (NOP regime). The above treatment produced an objective therapeutic response in 33% of the patients, in 50% a partial response, in 17% it failed. The median of survival in the whole group was 10.5 months. Substantially poorer therapeutic results were recorded in patients with primary resistance to the initial chemotherapy (objective response only in one of 6 patients) than in the group with secondary resistance which developed during a relapse of the disease (objective response in 3 of 6 patients). With the exception of marked leukopenia and neutropenia treatment by the NOP regime was very well tolerated. The NOP regime is an expedient approach which extends practical possibilities, in particular ambulatory treatment of refractory forms of multiple myeloma.

Adult↗
PubMed1991

Karyotypic abnormalities and their clinical aspects in multiple myeloma.

Chromosome studies were done on 56 patients with multiple myeloma to investigate their chromosomal abnormalities and to evaluate their clinical significance. Abnormal karyotype was found in 25 patients (44.6%), no relationship was seen between the frequency of chromosomal aberrations and age, sex, immunoglobulin isotype, bone marrow plasmocyte number and previous cytostatic therapy. Hyperdiploid and hypodiploid karyotypes were present in 10 and 13 patients, the chromosomes 1, 11 and 14 most often participated in structural rearrangements. Good relationship was observed between the frequency of chromosomal aberrations and the clinical stage and activity of the disease. In most of the patients with resistance to chemotherapy, abnormal karyotypes were observed. After the cytogenetic examination, the survival was significantly shorter for patients in whom an abnormal karyotype was identified (median survival 19 months) than for patients in whom only normal metaphases were observed (median survival 42 months).

Chromosome Aberrations↗
PubMed1991

Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.

In 71 patients with multiple myeloma the authors evaluated the clinical significance and the prognostic relevance of Bataille's stratification system based on serum beta 2-microglobulin and serum albumin levels. This staging system, which classified the patients to low, intermediate and poor risk groups (stages 1-3) showed a rather small prognostic significance, and it stratified our myeloma patients unsatisfactorily. On the basis of the results of our own analyses, we have developed our own modification of a pilot stratification system. We have verified its good clinical applicability and its powerful prognostic prediction. In this study, the good prognostic significance of serum beta 2-microglobulin and albumin levels (with the best cut-off levels of 4.0 mg/l and 35.0 g/l) and a good correlation between both analysed markers were confirmed.

Adult↗
PubMed1991

Malignant lymphoma involving the heart.

In a group of 116 patients with different types of malignant lymphoma, the frequency, type and clinical manifestations of heart involvement are evaluated. A case of primary cardiac lymphoma is demonstrated. Along with this, clinical and pathological findings in 15 further subjects with secondary lymphomatous infiltration of the heart are discussed; attention is being paid also to indirect factors causing cardiovascular damage, including radio- and chemotherapy.

Female↗
PubMed1991

Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.

In the group of 78 patients with multiple myeloma a comparison of the clinical significance of measured and corrected serum beta 2-microglobulin levels was carried out. There was confirmed a significant relationship between serum beta 2-microglobulin and serum creatinine levels. Pretreatment and follow-up of uncorrected serum beta 2-microglobulin levels were useful in confirming tumor mass grade (assessed according to Durie and Salmon or the British Medical Research Council) and survival prediction. No gain was evident from correcting the serum beta 2-microglobulin for the level of serum creatinine (according to Cassuto et al or Garewal et al).

Analysis of Variance↗
PubMed1991

[Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].

In a group of 71 patients with multiple myeloma the importance of beta 2-microglobulin (S-B2M) serum levels was evaluated with regard to their importance for monitoring of the disease. No significant relationship was found between B2M levels and monoclonal serum immunoglobulin, only in one third of the patients parallel changes of the two proteins were observed. One third of the patients had permanently normal S-B2M values and thus could not be evaluated with regard to the therapeutic results, 9% of the patients had very low S-B2M values throughout the disease regardless of the high activity of the latter and the marked increase of myeloma mass (stage III A). "Non-corrected" values of S-B2M proved useful in the evaluation of therapeutic results in patients with primarily elevated S-B2M values and satisfactory renal function but not in patients with elevated serum creatinine values. Normal or only slightly variable S-B2M values were part of the plateau phase of the disease, while during the relapse a rise of varying speed and extent occurred. S-B2M appears a suitable, though in some patients only supplementary, indicator for the long-term follow-up of the course of multiple myeloma.

Humans↗
PubMed1991

[Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].

The authors evaluated in a group of 89 patients with monoclonal gammapathy (18 patients with monoclonal gammapathy of undermined significance, 34 patients examined at the time of diagnosis of multiple myeloma (MM) and in a group of 71 patients with MM examined in different stages of the disease) the serum beta 2-microglobulin. It was revealed that the mentioned indicator is of no differential diagnostic value, it is not related to sex nor to the immunochemical type of monoclonal immunoglobulin. A relationship of serum beta 2-microglobulin to age, serum urea and serum creatinine, to the severity of anaemia, serum albumin, sedimentation rate of red cells, degree of infiltration of bone marrow by myeloma plasmocytes and the stage of the disease, evaluated by the systems of Durie-Salmon and Medical Research Council, was found. The authors tested the importance of serum levels of this indicator for the prognosis of the disease.

Aged↗
PubMed1991

[The iron reserve status in patients on regular dialysis treatment].

The authors examined the iron level, total plasma iron binding capacity, serum ferritin, the red cell haemogram and iron reserves in bone marrow of 31 patients with chronic renal failure who had regular dialyzation treatment. In 24 patients (77%) they did not detect any iron reserves in bone marrow, 22 of these patients had serum ferritin levels lower than 100 micrograms/l. The authors found a significant correlation between serum ferritin and the iron reserves in bone marrow and confirmed that assessment of serum ferritin is the most reliable non-invasive method for assessment of iron deficiency of the organism. At the same time they draw attention to the fact that the serum ferritin concentration suggesting iron deficiency in haemodialyzed patients is higher.

Adult↗
PubMed1990

Bone marrow necrosis intravitally recognized in four cases of blastic leukaemia.

Bone marrow necrosis (BMN) is a rare intravitally recognized finding in acute leukaemia with an uncertain clinical significance. The clinical events in 4 patients with AML, ALL, AMoL and blastic transformation of CGL in whom bone marrow cytology and histology revealed BMN are reviewed. One patient with BMN at clinical presentation of AML entered complete, long lasting remission with marrow restoration after the standard DAT therapy. In the three remaining patients survival after BMN diagnosis was 6, 11, and 14 weeks. Clinical, haematological, histological and marrow scanning findings and their significance for early diagnosis and means to asses the extent and evaluation of BMN will be discussed. In contrast to the most earlier reports, BMN does not appear to confer a poor prognosis in all patients with blastic leukaemia.

Acute Disease↗
PubMed1990

[Cytogenetic study in multiple myeloma. I. Chromosome findings in 56 patients].

The authors submit the results of cytogenetic examination of 56 patients with multiple myeloma. Chromosome changes were found in 25, i.e. 45% patients. Structural changes were found most frequently in chromosomes no. 1, 11 and 14, numerical changes in chromosomes 3, 4, 9, 11, 14, 16, 19, 21, 22, X and Y. Marker chromosomes were present above all in hyperdiploid mitoses. The authors did not detect a relationship of chromosome changes and the type of produced monoclonal immunoglobulin, nor a statistically significant difference in the frequency of chromosomal changes in treated and untreated patients. Hyperploidy and complex rearrangements of chromosomes were observed mainly during progression of the disease. In three of four patients with developed secondary plasmocellular leukaemia the authors found a chromosomal change 14q+, in two as a result of translocation 11/14.

Adult↗